CDA | Evidence Driven
CDA | Evidence Driven

ataluren

Details

Generic Name:
ataluren
Project Status:
Cancelled
Manufacturer:
PTC Therapeutics Canada ULC
Call for patient/clinician input open:
Brand Name:
Translarna
Project Line:
Reimbursement Review
Project Number:
SR0607-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​For the treatment of dystrophinopathy resulting from a nonsense mutation in the dystrophin gene.
Submission Type:
New
Fee Schedule:
Pending
Indications:
Dystrophinopathy
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : March 5, 2019